Serotonin, Serotonin Genetics(TPH2) and Emotion and Interference Processing

University of Electronic Science and Technology of China

Status: Unknown

Conditions: Healthy

Treatments: Drug: placebo treatment; Drug: ATD treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT03549182

UESTC-neuSCAN-51

Details and patient eligibility

About

The study aims to explore whether acute tryptophan depletion can affect the emotion and interference processing whether this effect is moderated by the TPH2 genotype

Full description

Based on previous studies suggesting that serotonin, a neurotransmitter, is associated with social & emotional behavior, including emotional reactivity and emotion regulation, the present study aims to explore effects of acute tryptophan depletion (ATD) on emotion processing and emotional interference processing within a randomized double-blind, with-subject, placebo-controlled pharmaco-fMRI experiment. To further examine the potential moderating effects of the genetic makeup of the serotonin system the present study will include a pharmacogenetics imaging approach. Given that TPH2 is the key regulator of the serotonergic signaling pathway, we therefore assessed whether such the effects of tryptophan depletion vary according to the TPH2 genotype. To this end, healthy male TPH2-GG or TPH2-TT carriers will be recruited and will receive ATD (100g) and placebo (102.3g) in a within subject design. To control for potential effects of pre-medication personality traits as well as effects of medicines on mood, subjects will be administered pre-treatment assessing relevant personality traits and post-treatment assessments of mood.

Enrollment: 50 estimated patients

Sex: Male

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects without past or current psychiatric or neurological disorders
• Right-handedness

Exclusion criteria

• History of head injury;
• Medical or psychiatric illness.
• High blood pressure, general cardio-vascular alterations
• History of drug or alcohol abuse or addiction.
• Allergy against medications or general strong allergies
• Sleep disorders.
• Visual or motor impairments

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

50 participants in 4 patient groups

male TPH2-GG carriers with ATD then placebo group

Experimental group

Description:

male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.

Treatment:

Drug: placebo treatment

Drug: ATD treatment

male TPH2-GG carriers with placebo then ATD group

Experimental group

Description:

male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.

Treatment:

Drug: placebo treatment

Drug: ATD treatment

male TPH2-TTcarriers with ATD then placebo group

Experimental group

Description:

male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.

Treatment:

Drug: placebo treatment

Drug: ATD treatment

male TPH2-TTcarriers with placebo then ATD group

Experimental group

Description:

male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.

Treatment:

Drug: placebo treatment

Drug: ATD treatment